# Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Study · id `cardio:ct-nct02347111` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02347111](<https://clinicaltrials.gov/study/NCT02347111>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02347111

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 162 participants.

## Technical summary

Registry record NCT02347111. Randomized; no masking; primary purpose treatment. Start 2020-12-31 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 162 participants (planned count; ClinicalTrials.gov record NCT02347111, source copy `cardio:ctgov-nct02347111-2025-08-24`, retrieved 2026-10-31)
- Started: 2020-12-31 (actual) (ClinicalTrials.gov record NCT02347111, source copy `cardio:ctgov-nct02347111-2025-08-24`, retrieved 2026-10-31)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT02347111, source copy `cardio:ctgov-nct02347111-2025-08-24`, retrieved 2026-10-31)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT02347111, source copy `cardio:ctgov-nct02347111-2025-08-24`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02347111, source copy `cardio:ctgov-nct02347111-2025-08-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02347111-2025-08-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- Condition: Atrial Fibrillation
- Intervention (Drug): Flecainide
- Intervention (Drug): Sotalol
- Lead sponsor: University of Illinois Chicago
- Lead sponsor class: OTHER
- Collaborator: Medtronic
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: University of Illinois Chicago (`cardio:org-university-of-illinois-chicago`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: 3666de46679f32247e6483e3e60cbc4866e41988a91120f855e3d1d0f7ce7fd0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
